Nuclear trapping through inhibition of exosomal export by indomethacin increases cytostatic efficacy of doxorubicin and pixantrone

Clinical Cancer Research

Volumn 22, Issue 2, 2016, Pages 395-404

  Koch, Raphael ^a,b   Aung, Thiha ^a   Vogel, Daniel ^a   Chapuy, Bjoern ^b   Wenzel, Dirk ^c   Becker, Sabrina ^a   Sinzig, Ursula ^a   Venkataramani, Vivek ^a   Von Mach, Tobias ^d   Jacob, Ralf ^e   Truemper, Lorenz ^a   Wulf, Gerald G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A3; DOXORUBICIN; INDOMETACIN; PIXANTRONE; TUMOR PROTEIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCA3 PROTEIN, HUMAN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYTOSTATIC AGENT; ISOQUINOLINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; B CELL LYMPHOMA; CELL TRANSPORT; CELL VIABILITY; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; EXOSOME; FLOW CYTOMETRY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL NUCLEUS; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; TUMOR CELL LINE;

ANTHRACYCLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOSTATIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXOSOMES; HUMANS; INDOMETHACIN; ISOQUINOLINES; LYMPHOMA, LARGE B-CELL, DIFFUSE;

EID: 84958973026     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0577     Document Type: Article

References (46)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42.
2. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy inmalignant lymphoma. Cancer 1976;38:1484-93.
3. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995;13: 2916-23.
4. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 2008;143:607-21.
5. Pettengell R, Coiffier B, Narayanan G, De Mendoza FH, Digumarti R, Gomez H, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012;13:696-706.
6. Papadatos-Pastos D, Pettengell R. Pixantrone:merging safety with efficacy. Exp Rev Hematol 2013;6:25-33.
7. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2002;2:569-79.
8. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic 2002;3:321-30.
9. Raposo G, Nijman HW, StoorvogelW, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1161-72.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9.
11. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-16.
12. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006;176:1375-85.
13. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008;22: 1576-86.
14. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, et al. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica 2009;94:1528-36.
15. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005;4:1595-604.
16. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A 2011;108:15336-41.
17. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006;12:4357-63.
18. Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, et al. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs 2012;23:51-64.
19. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003;9:493-501.
20. Savina A, Fader CM, Damiani MT, Colombo MI. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic 2005;6:131-43.
21. Testa JS, Apcher GS, Comber JD, Eisenlohr LC. Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin. J Immunol 2010;185:6608-16.
22. Tokuyasu KT. A technique for ultracryotomy of cell suspensions and tissues. J Cell Biol 1973;57:551-65.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))Method.Methods 2001;25:402-8.
24. Matsumura Y, Sakai H, Sasaki M, Ban N, Inagaki N. ABCA3-mediated choline-phospholipids uptake into intracellular vesicles in A549 cells. FEBS Lett 2007;581:3139-44.
25. Cheong N, Zhang H, Madesh M, Zhao M, Yu K, Dodia C, et al. ABCA3 is critical for lamellar body biogenesis in vivo. J Biol Chem 2007; 282:23811-7.
26. Papoutsi M, Kurz H, Schachtele C, Marme D, Christ B, Prols F, et al. Induction of the blood-brain barrier marker neurothelin/HT7 in endothelial cells by a variety of tumors in chick embryos. Histochem Cell Biol 2000;113:105-13.
27. Maguire AR, Plunkett SJ, Papot S, Clynes M, O'Connor R, Touhey S. Synthesis of indomethacin analogues for evaluation as modulators of MRP activity. Bioorg Med Chem 2001;9:745-62.
28. Song JH, Kim SH, Kim HJ, Hwang SY, Kim TS. Alleviation of the drugresistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin. Int J Oncol 2008; 32:931-6.
29. Ye CG, Wu WK, Yeung JH, Li HT, Li ZJ, Wong CC, et al. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein andMRP1expression. Cancer Lett 2011;304:90-6.
30. Hupfeld T, Chapuy B, Schrader V, Beutler M, Veltkamp C, Koch R, et al. Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance. Br J Haematol 2013;161:204-13.
31. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome release and lowpH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE 2014;9:e88193.
32. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
33. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10:43-73.
34. Sosnik A. Reversal of multidrug resistance by the inhibition of ATPbinding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. Adv Drug Deliv Rev 2013;65: 1828-51.
35. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. Pglycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413-21.
36. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATPbinding cassette drug transporters: Present status and challenges. Expert Opin Drug Metab Toxicol 2008;4:205-23.
37. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, Griesinger F, et al. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 2004;89:1395-7.
38. Overbeck TR, Hupfeld T, Krause D, Waldmann-Beushausen R, Chapuy B, Guldenzoph B, et al. Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel. Oncology 2013;84:362-70.
39. Adnan N, Buck DP, Evison BJ, Cutts SM, Phillips DR, Collins JG. DNA binding by pixantrone. Org Biomol Chem 2010;8:5359-66.
40. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012;11 Suppl 1: S21-36.
41. Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in humanmyocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 2013;344:467-78.
42. Seideman P, Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 1988;27:117-22.
43. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-50.
44. Benyahia B, Huguet S, Decleves X, Mokhtari K, Criniere E, Bernaudin JF, et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: Chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 2004;66: 65-70.
45. Yu L, Wu WK, Li ZJ, Liu QC, Li HT, Wu YC, et al. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol 2009;75:1364-73.
46. Elahian F, Kalalinia F, Behravan J. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol 2010;33: 113-9.